Brokerages Set Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Price Target at $36.00
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have covered the stock in the last year […]
David Malcom Rodman Jon Congleton Mineralys Therapeutics Inc Wells Fargo Company Schonfeld Strategic Advisors Securities Exchange Commission
Source: dailypolitical.com